Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference
TORONTO, June 12, 2014 /CNW/ - Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.
Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of Donnatal®, an adjunctive therapy in the treatment of IBS and acute enterocolitis, an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.
Concordia operates out of facilities in Oakville, Ontario, Bridgetown, Barbados, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn (near Chicago), Illinois, and Charlottesville, Virginia.
SOURCE Concordia Healthcare Corp.For further information:
Please visit www.concordiarx.com or contact:
Kristen van Vogt
416-815-0700 x 244
416-815-0700 x 225